Dimerix Limited (AU:DXB)

ASX:DXB

DXB

Dimerix Limited

RESEARCH TOOLSreports

Want to see AU:DXB full AI Analyst Report?

Dimerix Limited (DXB) Price & Analysis

98 Followers

DXB Stock Chart & Stats

AU$0.40

-AU$0.03(-5.00%)

At close: Jan 09 4:00 PM EST

AU$0.40

-AU$0.03(-5.00%)

Day’s Range― - ―

52-Week RangeAU$0.16 - AU$0.67

Previous CloseN/A

Volume4.60M

Average Volume (3M)1.47M

Market Cap

AU$99.07M

Enterprise ValueAU$72.62M

Total Cash (Recent Filing)AU$38.49M

Total Debt (Recent Filing)AU$33.42K

Price to Earnings (P/E)―

Beta2.40

Next Earnings

Sep 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding600,396,800

10 Day Avg. Volume1,720,426

30 Day Avg. Volume1,468,144

Financial Highlights & Ratios

PEG Ratio0.65

Price to Book (P/B)24.09

Price to Sales (P/S)256.86

P/FCF Ratio8.26

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.02

Revenue Forecast (FY)AU$18.30M

Bulls Say, Bears Say

Bulls Say

Focused Pipeline With Lead Asset DMX-200Dimerix’s clear focus on DMX-200 and an in-house drug discovery platform provides a durable development pathway. A defined lead program concentrates R&D spend, supports potential near-term clinical milestones or partnerships, and enables pipeline expansion without diluting strategic focus over months.

Strong Recent Revenue GrowthSustained year-on-year revenue growth near 70% indicates improving commercial traction or milestone/partnership receipts. Consistent top-line expansion improves runway for development programs, supports reinvestment in R&D, and reduces sole reliance on capital markets over a multi-month horizon.

Low Leverage And Solid Operating Cash ConversionA very low debt load combined with operating cash flow converting faster than accounting income gives financial flexibility. This conservative capital structure and positive OCF conversion reduce refinancing risk and help fund clinical programs or partnerships without immediate reliance on external debt.

Bears Say

Persistent Negative Profit MarginsOngoing negative EBIT and net margins show the business is not yet operating profitably and faces structural cost or scale challenges. Unless margins improve, the company will likely need sustained external funding to support trials and operations, pressuring long-term sustainability over months.

Very Negative ROEAn ROE near -99% signals severe capital inefficiency and that equity is being eroded by losses. This undermines shareholder value and often leads to dilution or restructuring. It is a durable sign the company must materially improve profitability or capital allocation to restore investor returns.

Sharply Declining Free Cash Flow GrowthA >300% decline in free cash flow growth indicates cash available after operations and investments has collapsed, raising the likelihood of financing needs. For a clinical-stage biotech this elevates the risk of dilutive capital raises or delayed programs, a material multi-month constraint.

Dimerix Limited News

Dimerix Highlights ACTION3 Trial De-Risking and Commercial Potential for DMX-200

Dimerix Limited ( ($AU:DXB) ) just unveiled an announcement. Dimerix Limited has released an updated investor presentation and...

1M ago

DXB

Dimerix Confirms Strong Statistical Power and Refines Strategy for Phase 3 FSGS Trial

The latest update is out from Dimerix Limited ( ($AU:DXB) ). Dimerix has confirmed that its Phase 3...

1M ago

DXB

Dimerix to Court Singapore Investors With Update on Phase 3 Kidney Drug

Dimerix Limited ( ($AU:DXB) ) has issued an announcement. Dimerix Limited has announced an updated venue and details...

2M ago

DXB

Dimerix Over-Recruits in Pivotal FSGS Phase 3 Trial as Last Adult Patient Dosed

Dimerix Limited ( ($AU:DXB) ) has issued an update. Dimerix has completed enrolment and first dosing of the...

3M ago

DXB

Dimerix Courts Investors With Perth and Singapore Briefings on FSGS Phase 3 Program

The latest announcement is out from Dimerix Limited ( ($AU:DXB) ). Dimerix Limited has invited existing and potential...

3M ago

DXB

Dimerix to Showcase Phase 3 FSGS Program at Oppenheimer Healthcare Conference

Dimerix Limited ( ($AU:DXB) ) has issued an announcement. Dimerix Limited will present an update on its Phase...

3M ago

DXB

Dimerix Revenue Surges but Loss Deepens and Asset Base Thins

Dimerix Limited ( ($AU:DXB) ) has provided an update. Biotechnology developer Dimerix Limited reported a sharp increase in...

4M ago

DXB

Dimerix to Showcase Phase 3 FSGS Program and Growth Strategy at Euroz Hartleys Healthcare Forum

Dimerix Limited ( ($AU:DXB) ) has issued an update. Dimerix Limited announced that CEO and Managing Director Dr...

4M ago

DXB

Dimerix Hits Phase 3 Recruitment Target for Lead Kidney Drug as FDA Backs Approval Pathway

Dimerix Limited ( ($AU:DXB) ) has issued an update. Dimerix reported strong operational progress in the December 2025...

4M ago

DXB

Dimerix Strengthens Leadership with Appointment of New CFO and Company Secretary

Dimerix Limited ( ($AU:DXB) ) just unveiled an update. Dimerix has appointed seasoned finance executive Mike Tonroe as...

5M ago

DXB

DXB FAQ

What was Dimerix Limited’s price range in the past 12 months?

Dimerix Limited lowest share price was AU$0.16 and its highest was AU$0.67 in the past 12 months.

What is Dimerix Limited’s market cap?

Dimerix Limited’s market cap is AU$99.07M.

When is Dimerix Limited’s upcoming earnings report date?

Dimerix Limited’s upcoming earnings report date is Sep 02, 2026 which is in 83 days.

How were Dimerix Limited’s earnings last quarter?

Dimerix Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.027.

Is Dimerix Limited overvalued?

According to Wall Street analysts Dimerix Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Dimerix Limited pay dividends?

Dimerix Limited does not currently pay dividends.

What is Dimerix Limited’s EPS estimate?

Dimerix Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Dimerix Limited have?

Dimerix Limited has 600,396,800 shares outstanding.

What happened to Dimerix Limited’s price movement after its last earnings report?

Dimerix Limited reported an EPS of -AU$0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.409%.

Which hedge fund is a major shareholder of Dimerix Limited?

Currently, no hedge funds are holding shares in AU:DXB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Dimerix Limited Stock Smart Score

Underperform

Fundamentals

Return on Equity

-278.87%

Trailing 12-Months

Asset Growth

194.65%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Dimerix Limited

Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient. The company's leading therapeutic candidate, DMX-200, is currently undergoing extensive clinical evaluation, including two separate Phase 3 trials targeting respiratory complications linked to COVID-19. DMX-200 is also in a distinct Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS), a severe kidney disorder, and is being developed for the treatment of diabetic kidney disease. Additionally, Dimerix is advancing DMX-700, which is intended for chronic obstructive pulmonary disease (COPD). The company's corporate headquarters are located in Fitzroy, Australia.